| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/10/2001 | WO2001033223A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032923A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 05/10/2001 | WO2001032900A1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 05/10/2001 | WO2001032898A2 Recombinant sendai virus vector for introducing exogenous genes to airway epithelia |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032864A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 05/10/2001 | WO2001032705A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032693A2 Trp-protein-related mtr1 protein and dna sequence coding therefor |
| 05/10/2001 | WO2001032691A1 Hcv ns3 protease inhibitors |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032685A2 Gene expression directed by a super-psa promoter |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032670A1 Oxetanone derivatives |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 05/10/2001 | WO2001032659A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
| 05/10/2001 | WO2001032656A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | WO2001032655A2 Quinoline and naphthyridine carboxylic acid antibacterials |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032651A1 Quinazoline derivatives as vegf inhibitors |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032646A2 Sulfonamide derivatives |
| 05/10/2001 | WO2001032640A1 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants |
| 05/10/2001 | WO2001032634A1 2-cyclohexyl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | WO2001032633A1 Substituted 5-benzyl-2,4-diaminopyrimidines |
| 05/10/2001 | WO2001032631A2 Heterocyclic cytotoxic agents |
| 05/10/2001 | WO2001032630A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032627A1 Process of making substituted pyrazoles |
| 05/10/2001 | WO2001032626A1 Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
| 05/10/2001 | WO2001032625A1 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032622A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032620A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032619A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032616A2 Oxetanone derivatives |
| 05/10/2001 | WO2001032615A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | WO2001032611A1 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032604A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032263A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032212A1 Drugs, drinks or foods |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032202A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | WO2001032189A1 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 05/10/2001 | WO2001032186A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 05/10/2001 | WO2001032176A1 Beta-carboline derivatives for use as analgesics |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032174A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032161A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032155A2 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2001 | WO2001032154A2 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 05/10/2001 | WO2001032149A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032128A2 Human chemokine beta-13 |
| 05/10/2001 | WO2001032127A2 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | WO2001019379A3 Methods for treating muscular dystrophy with bone marrow cells |
| 05/10/2001 | WO2001016306A3 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 05/10/2001 | WO2001016304A3 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/10/2001 | WO2001005393A3 Method for treating chronic pain using mek inhibitors |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000072666A3 USE OF TRANSGENIC MICE LACKING JunB EXPRESSION IN THE MYELOID LINEAGE |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO1999002514A3 Epothilone derivatives |
| 05/10/2001 | US20010001104 Thienopyridine compounds, their production and use |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | US20010001041 Homogenizing a tissue in a nondenaturing aqueous solvent to obtain particles; aqueous solvent extraction; separation of solid and liquid; fractionating and purifying; inhibitors of matrix metalloprotease and angiogenesis; antitumor agents |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2390077A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389973A1 Method of treating amyloid beta precursor disorders |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389778A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | CA2389773A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389655A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | CA2389643A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389574A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | CA2389543A1 Hcv ns3 protease inhibitors |
| 05/10/2001 | CA2389377A1 Substituted 5-benzyl-2,4-diaminopyrimidines |